BACKGROUND: We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. METHODS:Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency × severity) at baseline was compared to the end of treatment. RESULTS:Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. CONCLUSIONS:Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
RCT Entities:
BACKGROUND: We tested if magnesium would diminish bothersome hot flashes in breast cancerpatients. METHODS:Breast cancerpatients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency × severity) at baseline was compared to the end of treatment. RESULTS: Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. CONCLUSIONS: Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned.
Authors: S K Quella; C L Loprinzi; J A Sloan; N L Vaught; W L DeKrey; T Fischer; G Finck; N Pierson; T Pisansky Journal: Cancer Date: 1998-05-01 Impact factor: 6.860
Authors: Charles L Loprinzi; Ralph Levitt; Debra Barton; Jeff A Sloan; Shaker R Dakhil; Daniel A Nikcevich; James D Bearden; James A Mailliard; Loren K Tschetter; Tom R Fitch; John W Kugler Journal: J Clin Oncol Date: 2006-02-27 Impact factor: 44.544
Authors: Alexandra G Kazaks; Janet Y Uriu-Adams; Timothy E Albertson; Sonia F Shenoy; Judith S Stern Journal: J Asthma Date: 2010-02 Impact factor: 2.515
Authors: Haeseong Park; Rui Qin; Thomas J Smith; Pamela J Atherton; Debra L Barton; Keren Sturtz; Shaker R Dakhil; Daniel M Anderson; Kathleen Flynn; Suneetha Puttabasavaiah; Nguyet Anh Le-Lindqwister; Gilbert D A Padula; Charles L Loprinzi Journal: Menopause Date: 2015-06 Impact factor: 2.953
Authors: M Stanisławska; M Szkup-Jabłońska; A Jurczak; S Wieder-Huszla; A Samochowiec; A Jasiewicz; I Noceń; K Augustyniuk; A Brodowska; B Karakiewicz; D Chlubek; E Grochans Journal: Biol Trace Elem Res Date: 2013-11-24 Impact factor: 3.738